Yufeng Song , Cong Zhang , Dingchang Shao , Xiaoming Song , Dunsheng Han , Jinke Liu , Xuefeng Xie , Mingkun Zhao , Ziwei Wei , Guoxiong Xu , Shiyu Wang , Gang Chen
{"title":"CircRHOBTB3通过促进NONO的细胞质保留抑制前列腺癌的增殖和转移,从而抑制MAOA。","authors":"Yufeng Song , Cong Zhang , Dingchang Shao , Xiaoming Song , Dunsheng Han , Jinke Liu , Xuefeng Xie , Mingkun Zhao , Ziwei Wei , Guoxiong Xu , Shiyu Wang , Gang Chen","doi":"10.1016/j.canlet.2025.217910","DOIUrl":null,"url":null,"abstract":"<div><div>Prostate cancer (PCa) is one of the most prevalent malignant tumors affecting men. Metastatic PCa is generally considered incurable. Circular RNA (circRNA) is a distinct class of RNA implicated in the tumorigenesis and development of various cancers, including PCa. However, the specific role and underlying molecular mechanisms of circRNA in PCa remain poorly understood. This study identifies hsa_circ_0007444, generated from the back-splicing of exons 6–7 of the <em>Rho Related BTB Domain Containing 3 (RHOBTB3)</em> gene and named as circRHOBTB3, as being downregulated in PCa. Low expression of circRHOBTB3 correlates with elevated pathological T stage, clinical M stage, and D'Amico grade. Functionally, circRHOBTB3 inhibits PCa cell proliferation and metastasis both <em>in vitro</em> and <em>in vivo</em>. Mechanistically, circRHOBTB3 binds to the non-POU domain-containing octamer-binding protein (NONO), a transcription factor for monoamine oxidase A (MAOA), sequestering NONO in the cytoplasm and preventing it from upregulating MAOA transcription. This results in decreased MAOA expression, ultimately suppressing PCa cell proliferation and metastasis. Furthermore, the RNA binding protein serine/arginine-rich splicing factor 9 specifically interacts with AluSx and AluJb, inhibiting circRHOBTB3 circularization. In conclusion, this study identifies circRHOBTB3 as a tumor suppressor with potential to be a promising clinical biomarker and therapeutic target for metastatic PCa.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"631 ","pages":"Article 217910"},"PeriodicalIF":10.1000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CircRHOBTB3 suppresses MAOA by promoting cytoplasmic retention of NONO to inhibit prostate cancer proliferation and metastasis\",\"authors\":\"Yufeng Song , Cong Zhang , Dingchang Shao , Xiaoming Song , Dunsheng Han , Jinke Liu , Xuefeng Xie , Mingkun Zhao , Ziwei Wei , Guoxiong Xu , Shiyu Wang , Gang Chen\",\"doi\":\"10.1016/j.canlet.2025.217910\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Prostate cancer (PCa) is one of the most prevalent malignant tumors affecting men. Metastatic PCa is generally considered incurable. Circular RNA (circRNA) is a distinct class of RNA implicated in the tumorigenesis and development of various cancers, including PCa. However, the specific role and underlying molecular mechanisms of circRNA in PCa remain poorly understood. This study identifies hsa_circ_0007444, generated from the back-splicing of exons 6–7 of the <em>Rho Related BTB Domain Containing 3 (RHOBTB3)</em> gene and named as circRHOBTB3, as being downregulated in PCa. Low expression of circRHOBTB3 correlates with elevated pathological T stage, clinical M stage, and D'Amico grade. Functionally, circRHOBTB3 inhibits PCa cell proliferation and metastasis both <em>in vitro</em> and <em>in vivo</em>. Mechanistically, circRHOBTB3 binds to the non-POU domain-containing octamer-binding protein (NONO), a transcription factor for monoamine oxidase A (MAOA), sequestering NONO in the cytoplasm and preventing it from upregulating MAOA transcription. This results in decreased MAOA expression, ultimately suppressing PCa cell proliferation and metastasis. Furthermore, the RNA binding protein serine/arginine-rich splicing factor 9 specifically interacts with AluSx and AluJb, inhibiting circRHOBTB3 circularization. In conclusion, this study identifies circRHOBTB3 as a tumor suppressor with potential to be a promising clinical biomarker and therapeutic target for metastatic PCa.</div></div>\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"631 \",\"pages\":\"Article 217910\"},\"PeriodicalIF\":10.1000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304383525004781\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383525004781","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
前列腺癌(PCa)是影响男性最常见的恶性肿瘤之一。转移性前列腺癌通常被认为是无法治愈的。环状RNA (circRNA)是一类独特的RNA,与包括前列腺癌在内的各种癌症的发生和发展有关。然而,circRNA在PCa中的具体作用和潜在的分子机制仍然知之甚少。本研究发现hsa_circ_0007444在PCa中下调,该基因由Rho Related BTB Domain Containing 3 (RHOBTB3)基因外显子6-7的反剪接产生,命名为circRHOBTB3。circRHOBTB3低表达与病理T分期、临床M分期和D'Amico分级升高相关。在功能上,circRHOBTB3在体内和体外均能抑制PCa细胞的增殖和转移。从机制上说,circRHOBTB3与非pou结构域的八聚体结合蛋白(NONO)结合,将NONO隔离在细胞质中,阻止其上调MAOA的转录。这导致MAOA表达降低,最终抑制PCa细胞的增殖和转移。此外,RNA结合蛋白丝氨酸/精氨酸丰富剪接因子9特异性地与AluSx和AluJb相互作用,抑制circRHOBTB3环状化。总之,本研究确定circRHOBTB3是一种肿瘤抑制因子,有潜力成为转移性前列腺癌的临床生物标志物和治疗靶点。
CircRHOBTB3 suppresses MAOA by promoting cytoplasmic retention of NONO to inhibit prostate cancer proliferation and metastasis
Prostate cancer (PCa) is one of the most prevalent malignant tumors affecting men. Metastatic PCa is generally considered incurable. Circular RNA (circRNA) is a distinct class of RNA implicated in the tumorigenesis and development of various cancers, including PCa. However, the specific role and underlying molecular mechanisms of circRNA in PCa remain poorly understood. This study identifies hsa_circ_0007444, generated from the back-splicing of exons 6–7 of the Rho Related BTB Domain Containing 3 (RHOBTB3) gene and named as circRHOBTB3, as being downregulated in PCa. Low expression of circRHOBTB3 correlates with elevated pathological T stage, clinical M stage, and D'Amico grade. Functionally, circRHOBTB3 inhibits PCa cell proliferation and metastasis both in vitro and in vivo. Mechanistically, circRHOBTB3 binds to the non-POU domain-containing octamer-binding protein (NONO), a transcription factor for monoamine oxidase A (MAOA), sequestering NONO in the cytoplasm and preventing it from upregulating MAOA transcription. This results in decreased MAOA expression, ultimately suppressing PCa cell proliferation and metastasis. Furthermore, the RNA binding protein serine/arginine-rich splicing factor 9 specifically interacts with AluSx and AluJb, inhibiting circRHOBTB3 circularization. In conclusion, this study identifies circRHOBTB3 as a tumor suppressor with potential to be a promising clinical biomarker and therapeutic target for metastatic PCa.
期刊介绍:
Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research.
Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy.
By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.